You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMagnesium salicylate
Accession NumberDB01397
TypeSmall Molecule
GroupsApproved
DescriptionMagnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain. It is also used to treat headaches, general back pain, and certain joint pains like arthritis. It is found in a variety of over-the-counter (OTC) medications as an anti-inflammatory, primarily for back-pain relief. Magnesium Salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflamatory and pain-relieving effects. Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results.
Structure
Thumb
Synonyms
Magnesium salicylate anhydrous
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arthriten TabletsTablet325 mgOralAlva Amco Pharmacal Companies, Inc.2003-05-152006-07-27Canada
Back-ese M Tab 325mgTablet325 mgOralG.T. Fulford Pharmaceuticals1985-12-311998-06-25Canada
Back-ese M Tablets 325 mgTablet325 mgOralDannorth Laboratories Inc.1980-12-312000-07-19Canada
Backache AidTablet, film coated580 mg/1OralL&R Distributors, Inc.1998-11-07Not applicableUs
Backache ReliefTablet, film coated580 mg/1OralRite Aid Corporation1998-11-07Not applicableUs
Backache ReliefTablet, film coated580 mg/1OralCVS Pharmacy1998-11-07Not applicableUs
Backache Relief Extra StrengthTablet, film coated580 mg/1OralL.N.K. International, Inc.1998-11-07Not applicableUs
Backache Relief Extra StrengthTablet580 mg/1OralWalgreen Company1998-11-072018-04-10Us
Doan's Backache Pills 325mgTablet325 mgOralNovartis Consumer Health Canada Inc.1988-12-311998-07-08Canada
Doans Extra StrengthTablet580 mg/1OralDr. Reddy's Laboratories Inc.2013-05-15Not applicableUs
Extra Strength Backache ReliefCapsule580 mg/1OralFamily Dollar1998-11-07Not applicableUs
HerbogesicTablet650 mgOralSeroyal International Inc.1988-12-312009-07-06Canada
Kneerelief TabletsTablet650 mgOralAlva Amco Pharmacal Companies, Inc.2003-05-152006-07-27Canada
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Back ReliefNorth Safety Products LLC
Diurex Water PillsAlva Amco Pharmacal Companies, Inc.
Medique Back Pain OffUnifirst First Aid Corporation
Otis Clapp Back QuellUnifirst First Aid Corporation
Pain Aid BrfZee Medical Inc
Pamprin Cramp Menstrual Pain ReliefChattem, Inc.
Trilisate TabPurdue Pharma
Vica-cetProvision Medical Products
Salts
Name/CASStructureProperties
Magnesium salicylate tetrahydrate
18917-95-8
Thumb
  • InChI Key: CWQGWAKCTBFURY-UHFFFAOYSA-J
  • Monoisotopic Mass: 368.05938842
  • Average Mass: 368.577
DBSALT001864
Categories
UNIIJQ69D454N1
CAS number18917-89-0
WeightAverage: 298.531
Monoisotopic: 298.03277995
Chemical FormulaC14H10MgO6
InChI KeyMQHWFIOJQSCFNM-UHFFFAOYSA-L
InChI
InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2
IUPAC Name
magnesium(2+) ion bis(2-hydroxybenzoate)
SMILES
[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
Pharmacology
IndicationMagnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionMost NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. COX catalyzes the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinyes
inhibitor
HumanP23219 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Magnesium salicylate Action PathwayDrug actionSMP00698
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with 5-androstenedione.Experimental, Illicit
AbciximabMagnesium salicylate may increase the anticoagulant activities of Abciximab.Approved
AcebutololMagnesium salicylate may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aceclofenac.Approved
AcenocoumarolMagnesium salicylate may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Magnesium salicylate.Approved, Vet Approved
AclarubicinMagnesium salicylate may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Magnesium salicylate.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Aldosterone.Experimental
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium salicylate.Approved
AlfacalcidolThe serum concentration of Magnesium salicylate can be increased when it is combined with Alfacalcidol.Approved, Nutraceutical
AliskirenMagnesium salicylate may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololMagnesium salicylate may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Amcinonide.Approved
AmikacinMagnesium salicylate may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMagnesium salicylate may decrease the antihypertensive activities of Amiloride.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium salicylate.Approved
AmrinoneThe risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium salicylate.Approved
AmrubicinMagnesium salicylate may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMagnesium salicylate may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Anisodamine.Investigational
annamycinMagnesium salicylate may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Antipyrine.Approved
Antithrombin III humanMagnesium salicylate may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Magnesium salicylate may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanMagnesium salicylate may increase the anticoagulant activities of Apixaban.Approved
ApramycinMagnesium salicylate may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Apremilast.Approved, Investigational
ArbekacinMagnesium salicylate may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinMagnesium salicylate may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanMagnesium salicylate may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMagnesium salicylate may decrease the antihypertensive activities of Arotinolol.Approved
AtenololMagnesium salicylate may decrease the antihypertensive activities of Atenolol.Approved
Atracurium besylateMagnesium salicylate may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Magnesium salicylate.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Azelnidipine is combined with Magnesium salicylate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Magnesium salicylate.Approved
AzimilideThe risk or severity of adverse effects can be increased when Azimilide is combined with Magnesium salicylate.Investigational
BalsalazideMagnesium salicylate may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Magnesium salicylate.Approved
BecaplerminMagnesium salicylate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMagnesium salicylate may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Magnesium salicylate.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Magnesium salicylate.Approved
BenidipineThe risk or severity of adverse effects can be increased when Benidipine is combined with Magnesium salicylate.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Benoxaprofen.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium salicylate.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Magnesium salicylate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Betamethasone.Approved, Vet Approved
BetaxololMagnesium salicylate may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Betulinic Acid.Investigational
BevantololMagnesium salicylate may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
BisoprololMagnesium salicylate may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMagnesium salicylate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMagnesium salicylate may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Magnesium salicylate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Bucillamine.Investigational
BucindololMagnesium salicylate may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Budesonide.Approved
BufuralolMagnesium salicylate may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideMagnesium salicylate may decrease the diuretic activities of Bumetanide.Approved
BupranololMagnesium salicylate may decrease the antihypertensive activities of Bupranolol.Approved
CaiThe risk or severity of adverse effects can be increased when Cai is combined with Magnesium salicylate.Investigational
CalcitriolThe serum concentration of Magnesium salicylate can be increased when it is combined with Calcitriol.Approved, Nutraceutical
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Magnesium salicylate.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Magnesium salicylate.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Magnesium salicylate.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Magnesium salicylate.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Magnesium salicylate.Approved, Vet Approved, Withdrawn
CarteololMagnesium salicylate may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMagnesium salicylate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Celecoxib.Approved, Investigational
CeliprololMagnesium salicylate may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMagnesium salicylate may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Magnesium salicylate.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Magnesium salicylate.Approved, Vet Approved
ChlortetracyclineMagnesium salicylate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Magnesium salicylate.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Magnesium salicylate.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Magnesium salicylate.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cinnarizine is combined with Magnesium salicylate.Approved
CinoxacinThe serum concentration of Cinoxacin can be decreased when it is combined with Magnesium salicylate.Approved, Withdrawn
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
Cisatracurium besylateMagnesium salicylate may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
Citric AcidMagnesium salicylate may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium salicylate.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clocortolone.Approved
ClodronateThe serum concentration of Clodronate can be decreased when it is combined with Magnesium salicylate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Magnesium salicylate.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Magnesium salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Curcumin.Investigational
CyclosporineMagnesium salicylate may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with D-Limonene.Investigational
Dabigatran etexilateMagnesium salicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMagnesium salicylate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMagnesium salicylate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarodipineThe risk or severity of adverse effects can be increased when Darodipine is combined with Magnesium salicylate.Experimental
DaunorubicinMagnesium salicylate may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DecamethoniumMagnesium salicylate may increase the neuromuscular blocking activities of Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Deferasirox.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium salicylate.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with dehydroepiandrosterone sulfate.Investigational
DemeclocyclineMagnesium salicylate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesirudinMagnesium salicylate may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Magnesium salicylate.Approved
DextranMagnesium salicylate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Magnesium salicylate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Magnesium salicylate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Magnesium salicylate may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Magnesium salicylate.Approved, Vet Approved
DicoumarolMagnesium salicylate may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Magnesium salicylate.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Magnesium salicylate.Approved
DihydrostreptomycinMagnesium salicylate may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Magnesium salicylate.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Magnesium salicylate.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Magnesium salicylate.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Magnesium salicylate.Approved
Dipotassium phosphateThe serum concentration of Dipotassium phosphate can be decreased when it is combined with Magnesium salicylate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Magnesium salicylate.Approved
Domoic AcidMagnesium salicylate may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Magnesium salicylate.Investigational
Doxacurium chlorideMagnesium salicylate may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxorubicinMagnesium salicylate may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineMagnesium salicylate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
DrospirenoneMagnesium salicylate may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ebselen.Investigational
Edetic AcidMagnesium salicylate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMagnesium salicylate may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Magnesium salicylate.Approved
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Magnesium salicylate.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Magnesium salicylate.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Magnesium salicylate.Approved
EnoxacinThe serum concentration of Enoxacin can be decreased when it is combined with Magnesium salicylate.Approved
EnoxaparinMagnesium salicylate may increase the anticoagulant activities of Enoxaparin.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Magnesium salicylate.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Epirizole.Approved
EpirubicinMagnesium salicylate may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMagnesium salicylate may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Magnesium salicylate.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Magnesium salicylate.Approved
EquileninThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Equilin.Approved
EsmololMagnesium salicylate may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Estrone sulfate.Approved
Etacrynic acidMagnesium salicylate may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Magnesium salicylate.Approved, Investigational
Ethyl biscoumacetateMagnesium salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium salicylate.Approved
EtodolacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium salicylate.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fenbufen.Approved
FendilineThe risk or severity of adverse effects can be increased when Fendiline is combined with Magnesium salicylate.Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Magnesium salicylate.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Magnesium salicylate.Vet Approved
FleroxacinThe serum concentration of Fleroxacin can be decreased when it is combined with Magnesium salicylate.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Magnesium salicylate.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fludrocortisone.Approved
FluindioneMagnesium salicylate may increase the anticoagulant activities of Fluindione.Investigational
FlumequineThe serum concentration of Flumequine can be decreased when it is combined with Magnesium salicylate.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flumethasone.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium salicylate.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Magnesium salicylate.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Magnesium salicylate.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Magnesium salicylate.Approved, Nutraceutical, Vet Approved
FondaparinuxMagnesium salicylate may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMagnesium salicylate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Magnesium salicylate.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Magnesium salicylate.Approved
FramycetinMagnesium salicylate may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMagnesium salicylate may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabapentinMagnesium salicylate may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
GabexateMagnesium salicylate may increase the anticoagulant activities of Gabexate.Investigational
Gallamine TriethiodideMagnesium salicylate may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe risk or severity of adverse effects can be increased when Gallopamil is combined with Magnesium salicylate.Investigational
GarenoxacinThe serum concentration of Garenoxacin can be decreased when it is combined with Magnesium salicylate.Investigational
GatifloxacinThe serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Magnesium salicylate.Approved, Withdrawn
GemifloxacinThe serum concentration of Gemifloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
GeneticinMagnesium salicylate may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMagnesium salicylate may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMagnesium salicylate may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Magnesium salicylate.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with HE3286.Investigational
HeparinMagnesium salicylate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Higenamine.Investigational
HirulogMagnesium salicylate may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with HMPL-004.Investigational
HydralazineMagnesium salicylate may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Magnesium salicylate.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Magnesium salicylate.Approved
Hygromycin BMagnesium salicylate may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Magnesium salicylate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Icatibant.Approved
IdarubicinMagnesium salicylate may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxMagnesium salicylate may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Magnesium salicylate.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Magnesium salicylate.Approved
IndenololMagnesium salicylate may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Magnesium salicylate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Indoprofen.Withdrawn
INNO-206Magnesium salicylate may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Magnesium salicylate.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Isoxicam.Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium salicylate.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Istaroxime.Investigational
KanamycinMagnesium salicylate may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Magnesium salicylate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Magnesium salicylate.Approved
LabetalolMagnesium salicylate may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Magnesium salicylate.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium salicylate.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Magnesium salicylate.Approved, Investigational
LepirudinMagnesium salicylate may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium salicylate.Approved, Investigational
LevobunololMagnesium salicylate may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Magnesium salicylate.Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Magnesium salicylate.Approved
Lipoic AcidMagnesium salicylate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Nutraceutical
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Magnesium salicylate.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Magnesium salicylate.Approved
LomefloxacinThe serum concentration of Lomefloxacin can be decreased when it is combined with Magnesium salicylate.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Magnesium salicylate.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Magnesium salicylate.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Magnesium salicylate.Vet Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium salicylate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Manidipine is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Magnesium salicylate.Approved
ME-609The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Magnesium salicylate.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Magnesium salicylate.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Magnesium salicylate.Approved, Vet Approved
MesalazineMagnesium salicylate may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Magnesium salicylate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Magnesium salicylate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMagnesium salicylate may decrease the antihypertensive activities of Metipranolol.Approved
MetocurineMagnesium salicylate may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideMagnesium salicylate may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Magnesium salicylate.Approved
MetoprololMagnesium salicylate may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMagnesium salicylate may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MibefradilThe risk or severity of adverse effects can be increased when Mibefradil is combined with Magnesium salicylate.Withdrawn
MinocyclineMagnesium salicylate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Magnesium salicylate.Approved
MivacuriumMagnesium salicylate may increase the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Magnesium salicylate.Approved
MometasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Magnesium salicylate.Approved
MoxifloxacinThe serum concentration of Moxifloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Magnesium salicylate.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium salicylate.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nabumetone.Approved
NadololMagnesium salicylate may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMagnesium salicylate may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMagnesium salicylate may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Magnesium salicylate.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Magnesium salicylate.Investigational
Nalidixic AcidThe serum concentration of Nalidixic Acid can be decreased when it is combined with Magnesium salicylate.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Magnesium salicylate.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with NCX 4016.Investigational
NeamineMagnesium salicylate may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinThe serum concentration of Nemonoxacin can be decreased when it is combined with Magnesium salicylate.Investigational
NeomycinMagnesium salicylate may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinMagnesium salicylate may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nepafenac.Approved
NetilmicinMagnesium salicylate may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium salicylate.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Magnesium salicylate.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Niflumic Acid.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Niguldipine is combined with Magnesium salicylate.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Niludipine is combined with Magnesium salicylate.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium salicylate.Approved
NimesulideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium salicylate.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium salicylate.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium salicylate.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nitroaspirin.Investigational
NorfloxacinThe serum concentration of Norfloxacin can be decreased when it is combined with Magnesium salicylate.Approved
OfloxacinThe serum concentration of Ofloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Magnesium salicylate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium salicylate.Approved
OlsalazineMagnesium salicylate may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Magnesium salicylate.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Orgotein.Vet Approved
OtamixabanMagnesium salicylate may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Magnesium salicylate.Approved
OxprenololMagnesium salicylate may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Oxyphenbutazone.Withdrawn
OxytetracyclineMagnesium salicylate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium salicylate.Approved
PancuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Parecoxib.Approved
ParomomycinMagnesium salicylate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinThe serum concentration of Pazufloxacin can be decreased when it is combined with Magnesium salicylate.Investigational
PefloxacinThe serum concentration of Pefloxacin can be decreased when it is combined with Magnesium salicylate.Approved
PenbutololMagnesium salicylate may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateMagnesium salicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium salicylate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Magnesium salicylate.Approved
PhenindioneMagnesium salicylate may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonMagnesium salicylate may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Magnesium salicylate.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Magnesium salicylate.Approved, Investigational
PinaveriumThe risk or severity of adverse effects can be increased when Pinaverium is combined with Magnesium salicylate.Approved
PindololMagnesium salicylate may decrease the antihypertensive activities of Pindolol.Approved
PipecuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirarubicinMagnesium salicylate may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMagnesium salicylate may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Magnesium salicylate.Approved, Investigational
PlicamycinMagnesium salicylate may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Magnesium salicylate.Approved
PractololMagnesium salicylate may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Magnesium salicylate.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Magnesium salicylate.Approved, Illicit, Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pregnenolone.Experimental
PrenylamineThe risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium salicylate.Withdrawn
ProbenecidThe serum concentration of Magnesium salicylate can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Propacetamol.Approved
PropranololMagnesium salicylate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Magnesium salicylate.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Magnesium salicylate.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Magnesium salicylate.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Magnesium salicylate.Vet Approved
Protein CMagnesium salicylate may increase the anticoagulant activities of Protein C.Approved
Protein S humanMagnesium salicylate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMagnesium salicylate may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinThe serum concentration of Prulifloxacin can be decreased when it is combined with Magnesium salicylate.Investigational
PTC299The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with PTC299.Investigational
PuromycinMagnesium salicylate may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrantelMagnesium salicylate may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Magnesium salicylate.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Magnesium salicylate.Approved
RaltegravirThe serum concentration of Raltegravir can be decreased when it is combined with Magnesium salicylate.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Magnesium salicylate.Approved
RapacuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Magnesium salicylate.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Resveratrol.Experimental, Investigational
ReviparinMagnesium salicylate may increase the anticoagulant activities of Reviparin.Approved
RibostamycinMagnesium salicylate may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Rimexolone.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium salicylate.Approved, Investigational
RivaroxabanMagnesium salicylate may increase the anticoagulant activities of Rivaroxaban.Approved
RocuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinThe serum concentration of Rosoxacin can be decreased when it is combined with Magnesium salicylate.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Magnesium salicylate.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Magnesium salicylate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Magnesium salicylate.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Magnesium salicylate.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Seratrodast.Approved, Investigational
SisomicinMagnesium salicylate may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
Sodium glycerophosphateThe serum concentration of Sodium glycerophosphate can be decreased when it is combined with Magnesium salicylate.Approved
Sodium phosphateThe serum concentration of Sodium phosphate can be decreased when it is combined with Magnesium salicylate.Approved
SotalolMagnesium salicylate may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMagnesium salicylate may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium salicylate.Approved
SpectinomycinMagnesium salicylate may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Magnesium salicylate.Approved
SpironolactoneMagnesium salicylate may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with SRT501.Investigational
StreptomycinMagnesium salicylate may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMagnesium salicylate may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SuccinylcholineMagnesium salicylate may increase the neuromuscular blocking activities of Succinylcholine.Approved
SulfasalazineMagnesium salicylate may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Magnesium salicylate.Approved
SulodexideMagnesium salicylate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Magnesium salicylate.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Magnesium salicylate.Approved, Withdrawn
TacrolimusMagnesium salicylate may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Magnesium salicylate.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Magnesium salicylate.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Magnesium salicylate.Approved
Technetium tc 99m etidronateThe serum concentration of Technetium tc 99m etidronate can be decreased when it is combined with Magnesium salicylate.Approved
Technetium Tc-99m MedronateThe serum concentration of Technetium Tc-99m Medronate can be decreased when it is combined with Magnesium salicylate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Magnesium salicylate.Approved, Investigational
TemafloxacinThe serum concentration of Temafloxacin can be decreased when it is combined with Magnesium salicylate.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Magnesium salicylate.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Magnesium salicylate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Teriflunomide.Approved
TetracyclineMagnesium salicylate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tiaprofenic acid.Approved
TiludronateThe serum concentration of Tiludronate can be decreased when it is combined with Magnesium salicylate.Approved, Vet Approved
TimololMagnesium salicylate may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tixocortol.Approved
TobramycinMagnesium salicylate may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Magnesium salicylate.Approved
TorasemideMagnesium salicylate may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Magnesium salicylate.Approved
TranilastThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Magnesium salicylate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Magnesium salicylate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMagnesium salicylate may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Magnesium salicylate.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Magnesium salicylate can be decreased when it is combined with Triethylenetetramine.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Trisalicylate-choline.Approved
TrovafloxacinThe serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium salicylate.Approved, Withdrawn
TubocurarineMagnesium salicylate may increase the neuromuscular blocking activities of Tubocurarine.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Magnesium salicylate.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinMagnesium salicylate may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Magnesium salicylate.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Magnesium salicylate.Approved
VecuroniumMagnesium salicylate may increase the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium salicylate.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Magnesium salicylate.Investigational
WarfarinMagnesium salicylate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMagnesium salicylate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium salicylate.Approved
Ym150Magnesium salicylate may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zaltoprofen.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Magnesium salicylate.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Magnesium salicylate.Approved, Investigational, Withdrawn
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium salicylate.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Zomepirac.Withdrawn
ZorubicinMagnesium salicylate may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Satishchandra P. Patel, Vinayak T. Bhalani, “Solid choline magnesium salicylate composition and method of preparing same.” U.S. Patent US5043168, issued May, 1954.

US5043168
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5741
Blood Brain Barrier+0.829
Caco-2 permeable+0.5941
P-glycoprotein substrateNon-substrate0.6758
P-glycoprotein inhibitor INon-inhibitor0.9704
P-glycoprotein inhibitor IINon-inhibitor0.9768
Renal organic cation transporterNon-inhibitor0.8975
CYP450 2C9 substrateNon-substrate0.7872
CYP450 2D6 substrateNon-substrate0.9101
CYP450 3A4 substrateNon-substrate0.7282
CYP450 1A2 substrateNon-inhibitor0.8837
CYP450 2C9 inhibitorNon-inhibitor0.5705
CYP450 2D6 inhibitorNon-inhibitor0.9113
CYP450 2C19 inhibitorNon-inhibitor0.8537
CYP450 3A4 inhibitorNon-inhibitor0.9421
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9021
Ames testNon AMES toxic0.9695
CarcinogenicityNon-carcinogens0.8587
BiodegradationReady biodegradable0.8277
Rat acute toxicity2.3552 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.952
hERG inhibition (predictor II)Non-inhibitor0.9555
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral325 mg
Tablet, film coatedOral580 mg/1
Tablet, coatedOral
TabletOral580 mg/1
CapsuleOral580 mg/1
TabletOral650 mg
Tablet, film coatedOral
Prices
Unit descriptionCostUnit
Tricosal 1000 mg tablet1.23USD tablet
Choline mag trisal 1 gm tablet1.15USD tablet
Choline mag trisal 750 mg tablet0.81USD tablet
Novasal 600 mg tablet0.75USD tablet
Choline mag trisal 500 mg tablet0.64USD tablet
Doan's ex strength 580 mg tablet0.22USD tablet
CVS Pharmacy backache rlf 580 mg caplet0.18USD caplet
Doan's regular 325 mg tablet0.18USD tablet
Keygesic-10 650 mg tablet0.05USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0686 mg/mLALOGPS
logP2.86ALOGPS
logP1.98ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylic acids
Alternative Parents
Substituents
  • Salicylic acid
  • Benzoic acid
  • Benzoyl
  • Phenol
  • Vinylogous acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Organic zwitterion
  • Aromatic homomonocyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793 ]
  2. Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. [PubMed:15070163 ]
  3. Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. [PubMed:15106733 ]
  4. Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [PubMed:15199473 ]
  5. Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42. [PubMed:15348270 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. [PubMed:14746879 ]
  2. Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793 ]
  3. Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. [PubMed:15840771 ]
  4. Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. [PubMed:15871445 ]
  5. Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. [PubMed:16368818 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Zhang Q, Huang Y, Zhao R, Liu G, Chen Y: Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. doi: 10.1016/j.bios.2008.03.009. Epub 2008 Mar 21. [PubMed:18436441 ]
Comments
comments powered by Disqus
Drug created on July 08, 2007 11:04 / Updated on August 17, 2016 12:23